dexfenfluramine (Redux) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dexfenfluramine, marketed as dexfenfluramine hydrochloride under the name Redux, is a serotonergic anorectic drug: it reduces appetite by increasing the amount of extracellular serotonin in the brain. It is the d-enantiomer of fenfluramine and is structurally similar to amphetamine, but lacks any psychologically stimulating effects.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

adifax | dexfenfluramina | dexfenfluramine | dexfenfluramine hcl | dexfenfluramine hydrochloride | dexfenfluraminum | dextrofenfluramine | d-fenfluramine | d-n-ethyl-alpha-methyl-m-trifluoromethylphenethylamine | (+)-fenfluramine | redux | s-5614 hcl | (s)-fenfluramine | (s)-n-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine

Organizations (2)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Obesity (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Overview

  • Highest Phase: N/A
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue